Project Grant K24DA067322
- The National Institute on Drug Abuse awarded Johns Hopkins University $198,164 on October 17, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research examining barriers to medications for opioid use disorder (MOUD) treatment for individuals transitioning from correctional facilities to community settings. The research employs a complex systems approach combining quantitative and qualitative methods. Specific aims include examining the structure and function...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $155,500 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026, to develop and pilot the PROTECT-ED intervention, which addresses overdose and HIV prevention for individuals recently released from incarceration. The award funds research to refine and test an emergency department–based intervention designed to identify recently incarcerated patients and offer same-day medications for opioid...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $698,861 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research characterizing mitochondrial regulation of inflammaging in immune cells and neurons and its effects on cognitive function among people with HIV who use substances. The research addresses cognitive impairment affecting 30 to 60 percent of people with HIV, with persons who inject drugs representing a particularly...
- The National Institute on Drug Abuse, part of the Department of Health and Human Services National Institutes of Health, awarded the University of California, San Diego $192,930 in project grant funding on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports mentoring in patient-oriented research on central nervous system dysfunction in individuals with HIV and substance use. The funded activities provide protected time for the principal...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $147,037 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support patient-oriented research and mentorship on mechanisms of immunopathogenesis in chronic drug users. Dr. Jiang, a physician-scientist at MUSC with eight years of patient care experience in infectious diseases and 23 years of translational research experience, will conduct this mid-career development project...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $233,250 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for a community-based mixed-methods assessment of medetomidine and adulterated fentanyl withdrawal. The research characterizes how people who use drugs recognize and respond to medetomidine in local drug supplies, describes medetomidine withdrawal experiences, and develops transferable methods for rapid adulterant...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $1.731 million on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on immune mechanisms impacting the blood-brain barrier in people who inject drugs with and without HIV. The research examines how neuroimmune-blood-brain-barrier interactions contribute to cognitive complications among people with a history of injection drug use, particularly those coinfected with HIV....
- The National Institute on Drug Abuse awarded The Johns Hopkins University $146,215 on January 11, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a postdoctoral fellowship training Valerie Ganetsky for an independent research career focused on medication for opioid use disorder treatment, particularly for pregnant and postpartum women. The fellowship funds mentored research and training examining the association between buprenorphine dose trajectories and opioid...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $439,180 Project Grant effective September 1, 2025, through August 31, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279). This R21 exploratory/developmental grant supports research investigating dopaminergic neuronal-glial interactions in the striatum, with specific focus on understanding how HIV replication and methamphetamine exposure alter communication between...
- The National Institute on Drug Abuse awarded the University of California, San Diego $200,297 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support Dr. Nicole Kelly's mentored career development as a postdoctoral fellow transitioning to independent investigator status. The award funds Dr. Kelly's structured training program in implementation science and policy evaluation focused on expanding access to long-acting injectable treatments for HIV and opioid...
The National Institute on Drug Abuse awarded The Johns Hopkins University $197,320 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a K24 Midcareer Investigator Award in Patient-Oriented Research. The award provides protected time for Dr. Oluwaseun Falade-Nwulia, Associate Professor of Infectious Diseases at Johns Hopkins University, to expand a structured mentoring program for trainees and early-stage investigators focused on improving health outcomes for people who use drugs. Dr. Falade-Nwulia applies implementation science and behavioral economics to design and evaluate strategies that increase uptake of evidence-based interventions including HIV pre-exposure prophylaxis, antiretroviral therapy, direct-acting antivirals for hepatitis C virus, and medications for opioid use disorder. Her mentoring portfolio addresses the intersecting epidemics of HIV, hepatitis C virus, substance use disorders, and overdose. Through this award, Dr. Falade-Nwulia will establish the NUDGING Integrated Care and Engagement (NICE) program, a structured mentoring platform leveraging Johns Hopkins University School of Medicine and Bloomberg School of Public Health research and training infrastructure. Mentoring activities include longitudinal career development planning, structured works-in-progress sessions, and collaborative research engagement. The program aims to develop the next generation of independent physician-scientists and health services researchers conducting rigorous patient-oriented research focused on people who use drugs. The period of performance extends from August 15, 2026, through July 31, 2031, with work performed in Baltimore, Maryland.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $197.3k | 8/13/26 |